Immune system and intestinal microbiota determine efficacy of androgen deprivation therapy against prostate cancer
Background Prostate cancer (PC) responds to androgen deprivation therapy (ADT) usually in a transient fashion, progressing from hormone-sensitive PC (HSPC) to castration-resistant PC (CRPC). We investigated a mouse model of PC as well as specimens from PC patients to unravel an unsuspected contribut...
Main Authors: | Hang Phuong Pham, Douglas G McNeel, Laurence Zitvogel, Corentin Richard, Antoine Toubert, Guido Kroemer, Stéphane Culine, Karim Fizazi, Bertrand Routy, Lisa Derosa, Francesco Asnicar, Nicola Segata, Gladys Ferrere, Florent Ginhoux, Anne-Gaelle Goubet, Safae Terrisse, Kousuke Ueda, Andrew Maltez Thomas, Valentin Quiniou, Cassandra Thelemaque, Garett Dunsmore, Emmanuel Clave, Melissa Gamat-Huber, Satoru Yonekura, Conrad Rauber, Jean-Eudes Fahrner, Eugenie Pizzato, Pierre Ly, Marine Fidelle, Marine Mazzenga, Carolina Alves Costa Silva, Federica Armanini, Federica Pinto, Romain Daillère, Pierre Blanchard, Paule Opolon, Aymeric Silvin |
---|---|
Format: | Article |
Language: | English |
Published: |
BMJ Publishing Group
2022-03-01
|
Series: | Journal for ImmunoTherapy of Cancer |
Online Access: | https://jitc.bmj.com/content/10/3/e004191.full |
Similar Items
-
Elucidating the gut microbiota composition and the bioactivity of immunostimulatory commensals for the optimization of immune checkpoint inhibitors
by: Romain Daillère, et al.
Published: (2020-01-01) -
Resolving the Paradox of Colon Cancer Through the Integration of Genetics, Immunology, and the Microbiota
by: Marine Fidelle, et al.
Published: (2020-12-01) -
Microbiota-associated immunotherapy resistance caused by deficient PD-L2 - RGMb signaling
by: Marine Fidelle, et al.
Published: (2023-12-01) -
Bile acids regulate MAdCAM-1 expression to link the gut microbiota to cancer immunosurveillance
by: Marine Fidelle, et al.
Published: (2023-12-01) -
Influence of microbiota-associated metabolic reprogramming on clinical outcome in patients with melanoma from the randomized adjuvant dendritic cell-based MIND-DC trial
by: Carolina Alves Costa Silva, et al.
Published: (2024-02-01)